文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Hepatic arterial infusion chemotherapy in hepatocellular carcinoma: A bibliometric and knowledge-map analysis.

作者信息

Li Mei, Zhang Kai, He Ji'an, Zhang Weihao, Lv Tianye, Wang Li, Xing Wenge, Yu Haipeng

机构信息

Department of Interventional Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.

Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.

出版信息

Front Oncol. 2023 Jan 4;12:1071860. doi: 10.3389/fonc.2022.1071860. eCollection 2022.


DOI:10.3389/fonc.2022.1071860
PMID:36686799
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9846108/
Abstract

BACKGROUND: In recent years, hepatic arterial infusion chemotherapy (HAIC) has gained popularity in the treatment of hepatocellular carcinoma. Although several studies have been published, no bibliometric analysis have been conducted on this topic. OBJECTIVES: To understand the development status and future trends in the application of HAIC, we conducted bibliometric analysis to examine the cooperation and influence among countries, institutions, authors, and journals. METHODS: All relevant articles and reviews on the use of HAIC in HCC treatment were retrieved from the Web of Science database. A bibliometric analysis of countries, institutions, journals, authors, and keywords related to this field was performed using R and VOSviewer software. The main aspects analyzed were the research status and key fields of HAIC in HCC treatment. RESULTS: A total of 1026 articles published in 292 journals by 4937 authors from 959 institutions between 1974 and 2021 were retrieved. A rapid increase in articles published after 1990 was observed, which reached the peak in 2021. Japan had the most publications and citations. Yonsei University, Sun Yat-sen University, and Hiroshima University were the three leading institutions in research on this topic. Kwang-Hyub Han and Masatoshi Kudo have the greatest academic influence in this field. Most publications were made in the Hepato-Gastroenterology, whereas cancer had the most citations. The main aspects of HAIC treatment of HCC include HAIC and TACE, chemotherapy drug selection, HAIC and targeted therapy and immunotherapy, HAIC and surgery, and hepatotoxicity. Keywords such as FOLFOX, lenvatinib, hepatic arterial infusion chemotherapy are hot words in this field in recent years. CONCLUSION: The research on the use of HAIC in the treatment of HCC has been on the rise. Currently, HAIC combined with targeted therapy or immunotherapy has attracted significant attention.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/410a/9846108/d59775b15b83/fonc-12-1071860-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/410a/9846108/ccb9d5d6edb0/fonc-12-1071860-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/410a/9846108/fc2852d0108a/fonc-12-1071860-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/410a/9846108/66d27e87ba85/fonc-12-1071860-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/410a/9846108/d59775b15b83/fonc-12-1071860-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/410a/9846108/ccb9d5d6edb0/fonc-12-1071860-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/410a/9846108/fc2852d0108a/fonc-12-1071860-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/410a/9846108/66d27e87ba85/fonc-12-1071860-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/410a/9846108/d59775b15b83/fonc-12-1071860-g004.jpg

相似文献

[1]
Hepatic arterial infusion chemotherapy in hepatocellular carcinoma: A bibliometric and knowledge-map analysis.

Front Oncol. 2023-1-4

[2]
Bibliometric study of immunotherapy for hepatocellular carcinoma.

Front Immunol. 2023

[3]
Telomerase-related advances in hepatocellular carcinoma: A bibliometric and visual analysis.

World J Gastroenterol. 2024-3-7

[4]
Efficacy and Safety of HepaSphere Drug-Eluting Bead Transarterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy as the Second-Line Treatment in Advanced Hepatocellular Carcinoma.

J Hepatocell Carcinoma. 2024-3-4

[5]
Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.

Chin J Cancer. 2017-10-23

[6]
Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis.

Front Bioeng Biotechnol. 2022-9-27

[7]
Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.

J Gastroenterol. 2023-4

[8]
Mapping research trends of transarterial chemoembolization for hepatocellular carcinoma from 2012 to 2021: A bibliometric analysis.

World J Methodol. 2023-9-20

[9]
Survival benefit of neoadjuvant hepatic arterial infusion chemotherapy followed by hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus.

Front Pharmacol. 2023-9-19

[10]
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan.

Cancers (Basel). 2012-2-21

引用本文的文献

[1]
Interventional arterial chemotherapy versus sorafenib for advanced hepatocellular carcinoma in China: a health economic evaluation of open-label, randomised, phase 3 study.

BMJ Open. 2025-5-27

[2]
RALOX-HAIC (raltitrexed + oxaliplatin) combined with lenvatinib improves survival and safety in elderly patients with unresectable hepatocellular carcinoma.

BMC Cancer. 2025-5-16

[3]
Advanced hepatocellular carcinoma treatment strategies: Are transarterial approaches leading the way?

World J Gastrointest Oncol. 2025-1-15

[4]
A preliminary study of optimal treatment response rates in patients undergoing hepatic arterial infusion chemotherapy combined with molecular targeting and immunotherapy.

Front Immunol. 2024-4-10

本文引用的文献

[1]
Serum metabolic effects of corn oligopeptides with 7-day supplementation on early post-surgery primary liver cancer patients: a double-blind randomized controlled trial.

Hepatobiliary Surg Nutr. 2022-12

[2]
Comparative effectiveness of interventional therapeutic modalities for unresectable hepatocellular carcinoma: A systematic review and network meta-analysis.

Oncol Lett. 2022-8-31

[3]
Oxaliplatin Eluting CalliSpheres Microspheres for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.

Front Pharmacol. 2022-8-11

[4]
Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial.

Eur J Cancer. 2022-10

[5]
Bibliometric Analysis of the 100 Most Influential Hemangioblastoma Research Articles Illustrates Progress in Clinical Management and Room for Growth in Targeted Therapies.

World Neurosurg. 2022-10

[6]
Efficacy and safety of hepatic artery infusion chemotherapy with mFOLFOX in primary liver cancer patients with hyperbilirubinemia and ineffective drainage: a retrospective cohort study.

Ann Transl Med. 2022-4

[7]
The Global Research of Artificial Intelligence on Prostate Cancer: A 22-Year Bibliometric Analysis.

Front Oncol. 2022-3-1

[8]
Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study.

Front Immunol. 2022

[9]
Neoadjuvant intra-arterial versus intravenous chemotherapy in colorectal cancer.

Medicine (Baltimore). 2021-12-23

[10]
Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma.

Int J Mol Sci. 2021-11-28

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索